In hematological malignancy, Icaritin showed potent anti-leukemia activity in chronic myeloid leukemia in vitro and in vivo by regulating MAPK, AKT and JAK2/STAT3 signaling pathways [39]. The gene discussed is STAT3; the disease is leukemia.